Generation and phenotypic characterization of new human ovarian cancer cell lines with the identification of antigens potentially recognizable by HLA-restricted cytotoxic T cells

International Journal of Cancer

Volumn 73, Issue 1, 1997, Pages 143-150

  Ramakrishna, Venkatesh ^a   Negri, Donatella R M ^a   Brusic, Vladimir ^b   Fontanelli, Rosanna ^a   Canevari, Silvana ^a   Bolis, Giorgio ^a   Castelli, Chiara ^a   Parmiani, Giorgio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOLOGY; CYTOTOXIC T LYMPHOCYTE; HLA SYSTEM; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL;

ANTIGENS, NEOPLASM; EPITOPES; FEMALE; HLA ANTIGENS; HUMANS; OVARIAN NEOPLASMS; PHENOTYPE; POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0030798429     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970926)73:1<143::AID-IJC22>3.0.CO;2-G     Document Type: Article

References (32)

1. BOEL, P., WILDMANN, C., SENSI, M., BRASSEUR, R., RENAULD, J.-C., COUILE, P., BOON, T. and VAN DER BRUGGEN, P. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity. 2, 167-175 (1995).
2. BRUSIC, V., RUDY, G. and HARRISON, L.C., Prediction of MHC-binding peptides using artificial neural networks. In: R.J. Stonier and X.S. Yu (eds.), Complex systems: mechanisms of adaptation, pp. 253-260, IOS Press. Amsterdam (1994).
3. BRUSTIC, V. RUDY, G., KYNE, A.P. and HARRISON, L.C., MHCPEP - a database of MHC-binding peptides: update 1995. Nucleic Acids Res., 24, 242-244 (1996).
4. CANNISTRA, S.A., DEFRANZO, B., NILOFF, J. and OTTENSMEILR, C., Functional heterogeneity of CD44 molecules in ovarian cancer cell lines. Clin. Cancer Res., 1, 333-342 (1995).
5. CELIS, E., TSAI, V., CLAIRE, C., DEMARS, R., WENTWORTH, P.A., CHESTNUT, R.W., GREY. H.M., SETTE, A. and SERRA, H.M.. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptiue epitopes. Proc. nat. Acad. Sci. (Wash.). 91, 2105-2109 (1994).
6. CENTIS, F., TAGLIABUE, E., UPPUGUNDURI, S., PELLEGRINI, R., MARTIGONE, S., MASTROIANNI, A., MÉNARD, S. and COLNAGHI, M.I., p185 HER2/neu epitope mapping with murine monoclonal antibodies. Hybridoma, 11, 267-276 (1992).
7. CHICH, R.M. and URBAN, R.G., Analysis of MHC-presented peptides: applications in autoimmunity and vaccine development. Immunol. Today, 15, 155-160 (1994).
8. COM v. L.R., TOMASETTI, A., CARAYANNOPOULOS, L., FRASCA, V., KAMEN, B.A., COLNAGHI, M.I. and ZIRAWSKI JR., V.R., Cloning of a tumorassociated antigen: MOv18 and MOv19 antibodies recognize a folatebinding protein. Cancer Res., 51, 6125-6132 (1991).
9. DE PLAEN, E. and 14 OTHERS. Structure, chromosome localization and expression of 12 genes of the MAGE family. lmmunogenetics. 40, 360-369 (1994).
10. DISIS, M.L. and CHEEVER, M.A.. Oncogenic proteins as tumor antigens. Curr. Opin. Immunol., 8, 637-642 (1996).
11. + cytotoxic lymphocytes. Cancer Res., 57, 87-93 (1997a).
12. FISK, B., BLEVINS, T.L., WHARTON, J.T. and IOANNIDES, C.G., Identification of an immunodominant peptide of HER-2/neu prorooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J. exp. Med. 181, 2109-2117 (1995).
13. + CTL. Int. J. Oncol., 10, 159-169 (1997b).
14. GALLION, H.H., PIERETTI, M., DEPRIEST, P.D. and VAN NAGELL, J.R. JR., The molecular basis of ovarian cancer. Cancer (Suppl.), 76, 1992-1997 (1995).
15. GARRIDO, F., CABRERA, T., LOPEZ-NEVOT, M.A. and RUIZ-CABELLO, F., HLA class I antigens in human tumors. Adv. Cancer Res., 67, 155-195 (1995).
16. IOANMDES, C.G., FISK, B., JEROME, K.R., IRIMURA, T., WHARTON, J.T. and FINN, O.J., Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J. Immunol., 151, 3693-3703 (1993).
17. JONES, L.M.H., GARDNER, M.J., CATERALL, J.B. and TURNER, G.A. Hyaluronic acid secreted by mesoihelial cells: a natural barrier to ovarian cancer cell adhesion. Clin. exp. Metastasis, 13, 373-380 (1995).
18. MIOTTI, S., CANEVARI, S., MENARD, S., MEZZANZANICA, D., PORRO, G., PUPA, S.M., REGAZZONI, M., TAGLIABUE, E. and COLNAGHI, M.I., Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor specificity. Int. J. Cancer, 39, 297-303 (1987).
19. MOSCATELLO, D., HOLGADO-MADRKUGA, M., GODWIN, A.K., RAMIREZ, G., GUNN, G., ZOLTICK, P.W., BIEGEL, J.A., HAYES, R.L. and WONG, A.J., Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res., 55, 5536-5539 (1995).
20. PARKER, K.C., SHIKLDS, M., DIBRINO, M., BROOKS, A. and COLIGAN, J.K., Peptide binding to MHC Class I molecules: implications for antigenie poptido prediction. Immunol. Res., 14, 34-57 (1995).
21. PEOPLES, G.H., SMITH, R.C., LINEHAN, D.C., YOSMINO, I., GEDEGEBUURE, P.S. and EBERLEIN, T.J., Shared T cell epitopes in epithelial tumors. Cell. Immunol., 164, 279-280 (1995).
22. RAMMENSEE, H-G., FRIEDE, T. and STEVANOVIC, S., MHC-ligands and peptide motifs: first listing. Immunogenetics, 41, 178-228 (1995).
23. RIVOLTIMI, L., LOFTUS, D.J., BARRACCHINI, K., ARIENTI, F., MAZZOCCHI, A.. BIDDISON, W.E., SALALLER, M.L., APPELLA, E., PARMIANI, G. and MARINCOLA, F.M., Binding and presentation of peptides derived from melanoma antigens MART-1 and gp100 by HLA-A2 subtypes: implications for peptide-based immunotherapy. J. Immunol., 156, 3882-3891 (1996).
24. RUMELHART, D.E., HINTON, G.E. and WILLIAMS, R.J., Learning representations by back-propagating errors. Nature (Lond.), 323, 533-536 (1986).
25. RUSSO, V., DALERBA, P., RICCI, A., BONAZZI, C., LEONE, B.E., MANGIONI, C., ALLAVENA, P., BORDIGNON, C. and TRAVERSARI, C., MAGE, BAGE and GAGE gene expression in fresh epithelial ovarian carcinomas. Int. J. Cancer, 67, 457-460 (1996).
26. SLAMON, D.J., GODOLPHIN, W., JUNES, L.A., HOLT, J.A., WONG, S.O., KEITH, D.E. and LEVIN, W.J., Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science, 244, 707-712 (1989).
27. SWETS, J.A., Measuring the accuracy of diagnostic Systems. Science, 240, 1285-1293 (1988).
28. TAYLOR-PAPADIMITRIOU, J., PEAT, N., BUROCHLL, J., BEVERLEY, P. and SMITH, M., Potential for immunotheraphy: PEM as a target antigen. In: F. Sharp, P. Mason, T. Blackett and J. Berek (eds.). Ovarian cancer 3. pp. 305-315, Chitpman and Hall, London (1995).
29. 2 fragment against high- and low-EGFR-expressing capressing in nude mice. Int. J. Cancer. 62, 643-650 (1995).
30. VAN DEN EYNPE, B., PEETERS, O., DE BACKER, O., GAUGLER, B., LUCAS, S. and BOON, T., A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. exp. Med., 182, 689-698 (1995).
31. VAN DER BURG, S.U., VISSEREN, M.J.W., BRANPT, R.M.P., KAST, W.M. and MELIEF, C.J.M., Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J. Immunol., 156, 3308-3314 (1996).
32. YAMADA, A., KATAOKA, A., SHICHIJO, S., KAMURA, T., IMAI, Y., NISHIDA, T. and ITOH, K., Expression of MACE-1. MAGE-2, MAGE-3/-6 and MAGE4a/-4b genes in ovarian tumors. Int. J. Cancer (Pred. Oncol.), 64, 388-393 (1995).